CapWealth Advisors LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 7.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 230,364 shares of the company's stock after purchasing an additional 15,770 shares during the period. Merck & Co., Inc. makes up about 2.2% of CapWealth Advisors LLC's holdings, making the stock its 17th largest holding. CapWealth Advisors LLC's holdings in Merck & Co., Inc. were worth $20,677,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in MRK. Brighton Jones LLC raised its stake in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock valued at $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of Merck & Co., Inc. by 39.4% in the fourth quarter. Proficio Capital Partners LLC now owns 15,479 shares of the company's stock valued at $1,540,000 after acquiring an additional 4,373 shares in the last quarter. AlphaQuest LLC raised its stake in shares of Merck & Co., Inc. by 11.9% in the fourth quarter. AlphaQuest LLC now owns 11,636 shares of the company's stock valued at $1,158,000 after acquiring an additional 1,239 shares in the last quarter. American Assets Inc. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $398,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Merck & Co., Inc. by 6.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,020,503 shares of the company's stock valued at $101,520,000 after acquiring an additional 58,082 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, SVP Dalton E. Smart III sold 4,262 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the sale, the senior vice president directly owned 7,778 shares in the company, valued at approximately $643,707.28. This trade represents a 35.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.09% of the company's stock.
Merck & Co., Inc. Stock Performance
NYSE:MRK traded up $2.39 during mid-day trading on Wednesday, reaching $83.76. The stock had a trading volume of 6,687,533 shares, compared to its average volume of 16,221,200. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.16 and a current ratio of 1.41. The firm has a market capitalization of $210.31 billion, a price-to-earnings ratio of 12.19, a PEG ratio of 0.84 and a beta of 0.39. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $129.93. The business has a 50 day simple moving average of $79.09 and a 200 day simple moving average of $86.73.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $2.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.16 by $0.06. Merck & Co., Inc. had a net margin of 27.27% and a return on equity of 43.23%. The company had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. During the same period last year, the firm earned $2.07 EPS. The company's revenue for the quarter was down 1.6% on a year-over-year basis. On average, analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Tuesday, July 8th. Stockholders of record on Monday, June 16th were given a dividend of $0.81 per share. The ex-dividend date was Monday, June 16th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.87%. Merck & Co., Inc.'s payout ratio is 47.16%.
Analysts Set New Price Targets
Several research firms recently commented on MRK. Guggenheim reissued a "buy" rating and issued a $115.00 target price on shares of Merck & Co., Inc. in a report on Thursday, April 17th. Citigroup reaffirmed a "neutral" rating and set a $84.00 price objective (down previously from $115.00) on shares of Merck & Co., Inc. in a report on Wednesday, May 14th. Cantor Fitzgerald lowered Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a report on Tuesday, May 20th. Finally, Wall Street Zen lowered Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $109.19.
View Our Latest Stock Analysis on Merck & Co., Inc.
Merck & Co., Inc. Profile
(
Free Report)
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read More

Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report